Invivoscribe is dedicated to improving the quality of healthcare. We currently provide the majority of all DNA- and RNA-based molecular diagnostic reagents for leukemia and lymphoma testing worldwide.

The Media section provides reporters with easy access to Invivoscribe information and also contains our recent and archived press releases.

Current News Highlights

Insight Pharma Reports interviews Jeffrey E. Miller, PhD, CSO, CEO and Chairman of Invivoscribe board of directors regarding the field of Molecular Diagnostics: A Dynamic and Rapidly Broadening Market.
April 6, 2010 Report (64K / PDF)

Recent Press Releases

March 2010
TrovaGene, Inc., announces NPM1 testing available through Invivoscribe subsidiary, LabPMM

February 2010
Invivoscribe's subsidiary, LabFlow, announces launch of its proprietary comprehensive ERP software.

February 2010
Invivoscribe's subsidiary, LabPMM, announces release of NPM1 Mutation Assay & AML Mutation Panel

Upcoming Events

ESH-ICMLF 12th International Conference, September 24-26, 2010, Washington, D.C. USA

AMP 2010 Annual Meeting, November 17-20, 2010, San Jose, CA USA. Visit us at booth n°1515

52nd ASH Annual Meeting, December 4-7, 2010, Orlando, FL USA. Visit us at booth n°774

Media Inquiries
If you are a member of the media, please contact our Corporate Relations department.
Phone: +1 858 224-6600
Fax: +1 858 224-6601

Email: Corporate Relations

Quick Links
Medical Conditions
Research Focus
Development
Product Information
Views on Public Policy
LabPMM
FLT3 Gene Mutation

Invivoscribe Companies